Today, a brief rundown of news involving Bayer and Axsome Therapeutics, as well as updates from GSK, Novo Nordisk and Augustine Therapeutics that you may have missed.

今天，简要介绍您可能错过的涉及拜耳和Axsome Therapeutics的新闻，以及来自GSK、诺和诺德和Augustine Therapeutics的更新。

Bayer

拜耳

is adding to its cancer drug pipeline via a deal with China-based

通过与中国达成的协议，正在增加其癌症药物研发管道

Suzhou Puhe BioPharma

苏州普和生物制药

, securing a

，确保了

worldwide license

全球许可证

to a small molecule medicine that’s just begun Phase 1 testing. The medicine, now dubbed

一种刚刚开始第一阶段测试的小分子药物。这种药物，现在被称为

BAY 3713372

BAY 3713372

, blocks an enzyme known as PRMT5 that is thought to play a role in the cell cycle. Bayer will develop it for tumors that have deletions in a gene called MTAP, which is estimated to occur in 10% to 30% of all cancers, according to research cited by the company. Other developers, including

，阻断一种被称为PRMT5的酶，这种酶被认为在细胞周期中发挥作用。拜耳将开发用于治疗在名为MTAP的基因上有缺失的肿瘤，据公司引用的研究估计，这种情况出现在10%到30%的所有癌症中。其他开发者，包括

Amgen

安进公司

, are working on PRMT5 inhibitors, too. —

，也在研究PRMT5抑制剂。——

Ned Pagliarulo

内德·帕利亚鲁洛

A drug from

一种药物来自

Axsome Therapeutics

Axsome Therapeutics

reduced ADHD symptoms and severity more than a placebo did in a Phase 3 study of just over 500 adults, the company

在一项针对500多名成人的第三阶段研究中，该公司的药物比安慰剂更能减轻ADHD症状和严重程度。

said Tuesday

周二表示

. Results for a 150 milligram dose of the drug, called

。这种药物的150毫克剂量的结果，被称为

solriamfetol

索利安非托尔

, met the study’s primary and secondary goals after six weeks, but a higher, 300 milligram dose did not. This “inverse dose response” was flagged by several analysts and may have played a role in Axsome shares sinking by about 7% on Tuesday. The company plans to start a pediatric study later this year and also expects data this quarter from a study of solriamfetol in major depressive disorder.

，达到了研究的主要和次要目标，但较高剂量的300毫克却没有。这种“反向剂量反应”被多位分析师指出，可能在周二Axsome股价下跌约7%中起到了作用。该公司计划在今年晚些时候开始一项儿科研究，并且预计本季度还将获得索利氨非托在重度抑郁症研究中的数据。

— .

— .

Ned Pagliarulo

内德·帕利亚鲁洛

GSK

葛兰素史克

is partnering with the

正在与...合作

U.K. Dementia Research Institute

英国痴呆症研究所

and

和

Health Data Research U.K.

英国健康数据研究

to study whether its shingles vaccine can reduce the risk of dementia.

研究其带状疱疹疫苗是否可以降低痴呆症的风险。

The collaboration

合作

announced Tuesday builds on several retrospective

周二宣布的成果建立在多项回顾性研究的基础上

studies

研究

that have drawn a link between GSK’s Shingrix and neurodegenerative conditions, and will look at National Health Service data from 1.4 million 65- and 66-year-olds in the U.K. Shingrix

报道称，GSK的Shingrix与神经退行性疾病之间存在联系，并将研究英国140万名65岁和66岁老年人的国民健康服务数据。Shingrix

brought in

引入

£848 million, or a little over $1 billion in sales, in 2024. —

2024年，销售额达8.48亿英镑，或略超10亿美元。——

Gwendolyn Wu

格温多琳·吴

Novo Nordisk

诺和诺德

is expanding the availability of lower-priced

正在扩大低价位的可用性

Wegovy

韦哥维

, announcing Tuesday that uninsured or self-pay patients can buy the obesity drug for $499 per month at their local pharmacy. Previously, the lower cash price for the drug had only been available via Novo’s

，周二宣布未投保或自费患者可以以每月 499 美元的价格在本地药房购买这种减肥药。此前，该药物的较低现金价格只能通过诺和公司获得。

direct-to-consumer online pharmacy

直接面向消费者的在线药店

, launched earlier this month. People covered by Medicare or Medicaid aren’t eligible, nor are people on commercial insurance plans that cover Wegovy. The offering is Novo’s answer to

，于本月初推出。享受联邦医疗保险或医疗补助的人不符合条件，参加商业保险计划却涵盖 Wegovy 的人也不符合条件。这项服务是诺和诺德的应对之策。

Eli Lilly

礼来公司

’s

‘s

DTC and cash-pay programs

DTC和现金支付项目

for its rival weight loss drug

对于其竞争对手的减肥药

Zepbound

泽普绑定

. —

。 —

Ned Pagliarulo

内德·帕利亚鲁洛

Belgian biotechnology startup

比利时生物技术初创公司

Augustine Therapeutics

奥古斯丁治疗学

said Monday

周一表示

it raised €77.7 million euros, or $84.8 million, in a Series A round designed to bring part of its pipeline of central nervous system and cardiometabolic drugs into the clinic. AGT-100216, Augustine's lead program, targets a group of genetic disorders called Charcot-Marie-Tooth disease, which causes nerve damage in the arms and legs.

它在A轮融资中筹集了7770万欧元（8480万美元），用于将其部分中枢神经系统和心脏代谢药物管线推进到临床阶段。AGT-100216是Augustine的主导项目，针对一组称为夏科-马里-图斯病（Charcot-Marie-Tooth disease）的遗传性疾病，该疾病会导致手臂和腿部神经损伤。

Novo Holdings and Jeito Capital led the financing, which had backing from nine other investors including Eli Lilly and Asabys Partners. — .

诺和控股和Jeito Capital领投了此次融资，另有包括礼来公司和Asabys Partners在内的九家投资者支持。

Gwendolyn Wu

吴关琳